Morphosys AG, of Martinsried, Germany, said licensee Janssen Research & Development LLC, a unit of New Brunswick, N.J.-based Johnson & Johnson, presented results from a phase IIa study testing guselkumab, a fully human anti-IL-23 monoclonal antibody, in the treatment of active psoriatic arthritis. Data showed a substantially higher percentage of patients receiving guselkumab achieved at least a 20 percent improvement in signs and symptoms of the disease, or ACR20, at week 24, the study’s primary endpoint, compared with patients receiving placebo. Results also showed statistically significant improvements in all secondary endpoints, including physical function, psoriatic skin lesions and other health-related outcomes in patients treated with guselkumab compared with patients receiving placebo.